Diabetes classification
Reading File
Finding Sources
Searching PubMed
"diabetes mellitus"[MeSH Terms] AND "classification"[Title]
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive material from Harrison's, Robbins, and Henry's Clinical Diagnosis. Here is a structured overview of diabetes classification.
Classification of Diabetes Mellitus
The current etiologic classification (based on ADA standards) divides diabetes into four main categories:
I. Type 1 Diabetes Mellitus
Characterized by β-cell destruction, leading to absolute insulin deficiency. Patients require insulin for survival.
| Subtype | Features |
|---|---|
| Immune-mediated (Type 1A) | Autoimmune destruction of β-cells; autoantibodies present (GAD65, IA-2, IAA, ZnT8) |
| Idiopathic (Type 1B) | No evidence of autoimmunity; autoantibody-negative |
- Accounts for 5–10% of all diabetes
- Onset: any age, but most common in children and young adults
- C-peptide: very low or undetectable
- Insulin therapy is absolutely necessary
II. Type 2 Diabetes Mellitus
A combination of insulin resistance and progressive β-cell dysfunction (relative insulin deficiency).
- Accounts for 90–95% of all diabetes
- Strong genetic component; environmental factors (obesity, sedentary lifestyle) critical
- C-peptide: detectable
- Risk factors: obesity, advancing age, dyslipidemia, hypertension, polycystic ovarian syndrome, race/ethnicity
- Managed with lifestyle modification, oral agents, and/or insulin
III. Gestational Diabetes Mellitus (GDM)
- Glucose intolerance developing (or first recognized) during the second or third trimester of pregnancy
- Related to increased insulin demands from the metabolic/hormonal milieu of pregnancy
- Diabetes diagnosed in the first trimester is classified as pre-existing diabetes
- Increases risk of type 2 DM later in life for both mother and child
IV. Other Specific Types
A. Genetic Defects of β-Cell Function (MODY — Maturity-Onset Diabetes of the Young)
Monogenic diabetes due to single-gene mutations affecting β-cell development or function:
| MODY Type | Gene | Locus |
|---|---|---|
| MODY 1 | HNF4A | 20q12 |
| MODY 2 | GCK (glucokinase) | 7p13 |
| MODY 3 | HNF1A | 12q24.2 |
| MODY 4 | PDX1 | 13q12.1 |
| MODY 5 | HNF1B | 17q21 |
| MODY 6 | NEUROD1 | 2q31.3 |
| MODY 7–14 | KLF11, CEL, PAX4, INS, BLK, ABCC8, KCNJ11, APPL1 | Various |
Also includes:
- Neonatal diabetes (onset <6 months): mutations in KCNJ11, ABCC8, RFX6, insulin gene (>20 genetic defects identified)
- Transient neonatal diabetes
- Maternally inherited diabetes and deafness (MIDD): mitochondrial DNA mutation (m.3243A→G)
B. Genetic Defects in Insulin Action
- Type A insulin resistance
- Leprechaunism (Donohue syndrome) — INSR mutations
- Rabson-Mendenhall syndrome
- Lipodystrophy syndromes
C. Diseases of the Exocrine Pancreas ("Type 3c" / Pancreatogenic Diabetes)
- Chronic pancreatitis
- Pancreatectomy / trauma
- Pancreatic cancer / neoplasia
- Cystic fibrosis
- Hemochromatosis
- Fibrocalculous pancreatopathy
D. Endocrinopathies
- Acromegaly (GH excess)
- Cushing syndrome (cortisol excess)
- Glucagonoma
- Pheochromocytoma (catecholamine excess)
- Hyperthyroidism
- Somatostatinoma
- Aldosteronoma
E. Drug- or Chemical-Induced
- Glucocorticoids
- Thiazide diuretics
- β-adrenergic agonists
- Nicotinic acid
- Atypical antipsychotics (second-generation)
- Antiretroviral agents (protease inhibitors, NRTIs)
- Calcineurin/mTOR inhibitors (post-transplant)
- Pentamidine, diazoxide, statins, PCSK9 inhibitors
- Vacor (rodenticide)
F. Infections
- Congenital rubella
- Cytomegalovirus (CMV)
- Coxsackievirus B
G. Uncommon Immune-Mediated Forms
- "Stiff-person" syndrome
- Anti-insulin receptor antibodies
- Immune checkpoint inhibitor-associated diabetes (cancer therapy)
H. Other Genetic Syndromes
Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram syndrome, Friedreich ataxia, Huntington disease, Prader-Willi syndrome, myotonic dystrophy, porphyria, Laurence-Moon-Biedl syndrome
Comparison: Type 1 vs. Type 2 at a Glance
| Feature | Type 1 | Type 2 |
|---|---|---|
| Prevalence | 5–10% | 90–95% |
| Pathogenesis | Autoimmune β-cell destruction | Insulin resistance + β-cell dysfunction |
| Onset | Typically childhood/young adult | More common with age; can occur in youth |
| C-peptide | Very low/absent | Detectable |
| Autoantibodies | Present (GAD65, IA-2, IAA, ZnT8) | Absent |
| Insulin therapy | Always required | Often needed but not always initially |
| Prevention | None known | Lifestyle modification; metformin |
Sources:
- Harrison's Principles of Internal Medicine, 22e — Table 4.15-1
- Robbins, Cotran & Kumar Pathologic Basis of Disease — Table 24.6
- Henry's Clinical Diagnosis and Management by Laboratory Methods — Classification of Diabetes Mellitus
This is a shared conversation. Sign in to Orris to start your own chat.